Procedures
Participants underwent insertion of LAGB. Participants were randomised in a 1:1 ratio to either subcutaneous liraglutide 1.8 mg (Victoza) or placebo once daily within 6 weeks of surgery. Treatment allocation was fully concealed. Liraglutide was titrated as recommended to a maximum tolerated dose of 1.8 mg. The liraglutide/placebo intervention duration for each participant was 6 months (including the titration phase). Participants were followed up for 12 months and attended seven visits in total (Fig. Trial Flow Chart.